| Year |
Title |
Altmetric |
| 2021
|
Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - Reply.
JAMA Oncology.
7:635-636.
2021
|
|
| 2021
|
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden
2021
|
|
| 2021
|
New regimens and directions in the management of newly diagnosed multiple myeloma.
American Journal of Hematology.
96:367-378.
2021
|
|
| 2021
|
Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.
Journal of Geriatric Oncology.
12:256-261.
2021
|
|
| 2021
|
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
2021
|
|
| 2021
|
Daratumumab plus RVd for newly diagnosed multiple myeloma: Final analysis of the safety run-in cohort of GRIFFIN.
Blood Advances.
5:1092-1096.
2021
|
|
| 2021
|
Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.
Bone Marrow Transplantation.
2021
|
|
| 2021
|
Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States.
Cancer.
2021
|
|
| 2021
|
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Leukemia.
35:18-30.
2021
|
|
| 2021
|
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
American Journal of Hematology.
96:E5-E8.
2021
|
|
| 2020
|
Age is just a number, the wrong number.
Cancer.
126:5014-5016.
2020
|
|
| 2020
|
Defining and managing high-risk multiple myeloma: Current concepts
2020
|
|
| 2020
|
Treatments for newly diagnosed multiple myeloma: when endurance is interrupted
2020
|
|
| 2020
|
Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change.
Lancet Haematology.
7:e704-e706.
2020
|
|
| 2020
|
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biology of Blood and Marrow Transplantation.
26:e247-e255.
2020
|
|
| 2020
|
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation.
Bone Marrow Transplantation.
55:1810-1816.
2020
|
|
| 2020
|
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial.
Blood.
136:936-945.
2020
|
|
| 2020
|
Recent survival trends in diffuse large B-cell lymphoma––Have we made any progress beyond rituximab?.
Cancer Medicine.
9:5519-5525.
2020
|
|
| 2020
|
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
Clinical Lymphoma, Myeloma and Leukemia.
20:351-357.
2020
|
|
| 2020
|
Up-front autologous hematopoietic stem cell transplantation (AHSCT) from a single Brazilian center.
Bone Marrow Transplantation.
55:1181-1183.
2020
|
|
| 2020
|
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Biology of Blood and Marrow Transplantation.
26:798-804.
2020
|
|
| 2020
|
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.
JAMA Oncology.
6:1759-1765.
2020
|
|
| 2020
|
Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines
2020
|
|
| 2020
|
Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.
Biology of Blood and Marrow Transplantation.
2020
|
|
| 2020
|
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biology of Blood and Marrow Transplantation.
26:e7-e15.
2020
|
|
| 2019
|
Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.
British Journal of Haematology.
186:807-819.
2019
|
|
| 2019
|
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Biology of Blood and Marrow Transplantation.
25:1744-1755.
2019
|
|
| 2019
|
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Leukemia.
33:2266-2275.
2019
|
|
| 2019
|
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.
New England Journal of Medicine.
381:727-738.
2019
|
|
| 2019
|
Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors.
Leukemia Research.
82:1-6.
2019
|
|
| 2019
|
LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma.
Bone Marrow Transplantation.
54:625-628.
2019
|
|
| 2019
|
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
2019
|
|
| 2019
|
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study
2019
|
|
| 2019
|
Incidence and outcomes of rare paediatric non-hodgkin lymphomas.
British Journal of Haematology.
184:864-867.
2019
|
|
| 2019
|
Management of immunotherapy-related toxicities, version 1.2019
2019
|
|
| 2019
|
The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.
Biology of Blood and Marrow Transplantation.
25:e73-e75.
2019
|
|
| 2019
|
Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.
Biology of Blood and Marrow Transplantation.
25:233-238.
2019
|
|
| 2019
|
Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Biology of Blood and Marrow Transplantation.
25:73-85.
2019
|
|
| 2018
|
Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
Leukemia Research.
74:64-67.
2018
|
|
| 2018
|
A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801
2018
|
|
| 2018
|
Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.
Bone Marrow Transplantation.
53:1345-1348.
2018
|
|
| 2018
|
Second primary malignancy after multiple myeloma-population trends and cause-specific mortality.
British Journal of Haematology.
182:513-520.
2018
|
|
| 2018
|
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
Biology of Blood and Marrow Transplantation.
24:1379-1385.
2018
|
|
| 2018
|
Incidence and survival trends in mantle cell lymphoma.
British Journal of Haematology.
181:703-706.
2018
|
|
| 2018
|
Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation.
Biology of Blood and Marrow Transplantation.
24:909-913.
2018
|
|
| 2018
|
Infectious diarrhea in autologous stem cell transplantation: high prevalence of coccidia in a South American center.
Hematology, Transfusion and Cell Therapy.
40:132-135.
2018
|
|
| 2018
|
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: Final results from the PILLAR-2 randomized phase III trial.
Annals of Oncology.
29:707-714.
2018
|
|
| 2018
|
Incidence and outcomes of paediatric myelodysplastic syndrome in the United States.
British Journal of Haematology.
180:898-901.
2018
|
|
| 2018
|
Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.
American Journal of Hematology.
93:238-245.
2018
|
|
| 2018
|
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
British Journal of Haematology.
180:534-544.
2018
|
|
| 2018
|
Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma.
Journal of Clinical Oncology.
36:859-866.
2018
|
|
| 2017
|
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A center for international blood and marrow transplant research analysis.
Bone Marrow Transplantation.
52:1616-1622.
2017
|
|
| 2017
|
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study.
Hematological Oncology.
35:528-535.
2017
|
|
| 2017
|
C-MYC–positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy.
Cancer.
123:4411-4418.
2017
|
|
| 2017
|
Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
Cancer.
123:3141-3149.
2017
|
|
| 2017
|
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
American Journal of Hematology.
92:161-170.
2017
|
|
| 2017
|
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Biology of Blood and Marrow Transplantation.
23:269-277.
2017
|
|
| 2017
|
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.
Blood Advances.
1:282-287.
2017
|
|
| 2016
|
Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity
2016
|
|
| 2016
|
Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States.
Cancer.
122:3183-3190.
2016
|
|
| 2016
|
Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.
American Journal of Hematology.
91:1044-1051.
2016
|
|
| 2016
|
Mobilization of hematopoietic progenitor cells for autologous transportation: Consensus recommendations.
Revista da Associação Médica Brasileira.
62:10-15.
2016
|
|
| 2016
|
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
British Journal of Haematology.
175:55-65.
2016
|
|
| 2016
|
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
Biology of Blood and Marrow Transplantation.
22:1543-1551.
2016
|
|
| 2016
|
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
2016
|
|
| 2016
|
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Biology of Blood and Marrow Transplantation.
22:1197-1205.
2016
|
|
| 2016
|
Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome.
Journal of Clinical Oncology.
34:1864-1871.
2016
|
|
| 2016
|
Reply to a note on the magnitude of hazard ratios.
Cancer.
122:1299-1300.
2016
|
|
| 2016
|
Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum.
Biology of Blood and Marrow Transplantation.
22:564-570.
2016
|
|
| 2016
|
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features.
Cancer Causes and Control.
27:81-91.
2016
|
|
| 2016
|
Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.
American Journal of Hematology.
91:101-108.
2016
|
|
| 2015
|
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
2015
|
|
| 2015
|
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.
Bone Marrow Transplantation.
50:1513-1518.
2015
|
|
| 2015
|
Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study.
Journal of Clinical Oncology.
33:3741-3749.
2015
|
|
| 2015
|
A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.
Bone Marrow Transplantation.
50:1416-1423.
2015
|
|
| 2015
|
Nonbiological factors affecting survival in younger patients with acute myeloid leukemia.
Cancer.
121:3877-3884.
2015
|
|
| 2015
|
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.
Biology of Blood and Marrow Transplantation.
21:1746-1753.
2015
|
|
| 2015
|
Early mortality in multiple myeloma.
Leukemia.
29:1616-1618.
2015
|
|
| 2015
|
Fewer scans, better care.
Journal of Clinical Oncology.
33:1624.
2015
|
|
| 2015
|
Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.
Bone Marrow Transplantation.
50:197-203.
2015
|
|
| 2015
|
Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: Implications for survival and second malignancies
2015
|
|
| 2015
|
Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation.
Biology of Blood and Marrow Transplantation.
21:552-558.
2015
|
|
| 2015
|
Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.
Biology of Blood and Marrow Transplantation.
21:701-706.
2015
|
|
| 2015
|
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.
Biology of Blood and Marrow Transplantation.
21:1155-1166.
2015
|
|
| 2015
|
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphoma.
Cancer Control : Journal of the Moffitt Cancer Center.
22:87-94.
2015
|
|
| 2015
|
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
British Journal of Haematology.
169:219-227.
2015
|
|
| 2015
|
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
British Journal of Haematology.
168:796-805.
2015
|
|
| 2015
|
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
2015
|
|
| 2014
|
Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation.
Biology of Blood and Marrow Transplantation.
20:1729-1736.
2014
|
|
| 2014
|
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Blood.
124:1915-1925.
2014
|
|
| 2014
|
Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose.
Bone Marrow Transplantation.
49:1239-1240.
2014
|
|
| 2014
|
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations.
Biology of Blood and Marrow Transplantation.
20:295-308.
2014
|
|
| 2014
|
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality.
Journal of Clinical Oncology.
32:273-281.
2014
|
|
| 2014
|
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: Implications for risk-stratification.
Biology of Blood and Marrow Transplantation.
20:222-228.
2014
|
|
| 2014
|
Features and outcomes of diffuse large B-cell lymphoma of the thyroid in a large contemporary cohort
2014
|
|
| 2014
|
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
Biology of Blood and Marrow Transplantation.
20:402-408.e1.
2014
|
|
| 2014
|
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma.
Biology of Blood and Marrow Transplantation.
20:951-959.
2014
|
|
| 2014
|
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the american society for blood and marrow transplantation.
Biology of Blood and Marrow Transplantation.
20:1262-1273.
2014
|
|
| 2014
|
Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research.
Biology of Blood and Marrow Transplantation.
20:89-97.
2014
|
|
| 2014
|
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.
Transfusion.
54:3131-3137.
2014
|
|
| 2013
|
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
Blood.
122:3863-3870.
2013
|
|
| 2013
|
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
Biology of Blood and Marrow Transplantation.
19:1615-1624.
2013
|
|
| 2013
|
Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors.
Cancer.
119:3385-3392.
2013
|
|
| 2013
|
Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma.
Journal of Clinical Oncology.
31:3100-3109.
2013
|
|
| 2013
|
Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: An analysis of 3691 cases.
Blood.
121:4861-4866.
2013
|
|
| 2013
|
Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: Meta-analysis of trials with biological assignment.
Bone Marrow Transplantation.
48:562-567.
2013
|
|
| 2013
|
Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research.
Biology of Blood and Marrow Transplantation.
19:173-179.
2013
|
|
| 2012
|
Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients
2012
|
|
| 2012
|
Growth factor plus preemptive (just-in-time) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
Bone Marrow Transplantation.
47:1403-1408.
2012
|
|
| 2012
|
Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
European Journal of Haematology.
89:432-434.
2012
|
|
| 2012
|
Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysis.
Transfusion.
52:2375-2381.
2012
|
|
| 2011
|
Clonal diversity analysis using SNP microarray: A new prognostic tool for chronic lymphocytic leukemia.
Cancer Genetics.
204:654-665.
2011
|
|
| 2011
|
Beyond CD34+ cell dose: Impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Transfusion.
51:1995-2000.
2011
|
|
| 2011
|
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.
American Journal of Hematology.
86:699-701.
2011
|
|
| 2011
|
Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Biology of Blood and Marrow Transplantation.
17:1176-1181.
2011
|
|
| 2011
|
Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.
Blood.
118:282-288.
2011
|
|
| 2011
|
Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.
Bone Marrow Transplantation.
46:523-528.
2011
|
|
| 2011
|
Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
Bone Marrow Transplantation.
46:64-69.
2011
|
|
| 2010
|
Case report: Primary testicular lymphoma and AIDS.
Annals of Clinical and Laboratory Science.
40:75-79.
2010
|
|
| 2010
|
Testicular lymphoma.
Seminars in Oncology.
37:549-554.
2010
|
|
| 2010
|
Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure.
British Journal of Haematology.
151:94-96.
2010
|
|
| 2010
|
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
British Journal of Cancer.
103:796-801.
2010
|
|
| 2010
|
Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis.
American Journal of Hematology.
85:627-629.
2010
|
|
| 2010
|
Self-limited hemolysis due to anti-D passenger lymphocyte syndrome in allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplantation.
45:772-773.
2010
|
|
| 2009
|
Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.
British Journal of Haematology.
146:576-577.
2009
|
|
| 2009
|
Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma
2009
|
|
| 2008
|
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
British Journal of Haematology.
143:268-273.
2008
|
|
| 2008
|
Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
British Journal of Haematology.
142:404-412.
2008
|
|
| 2008
|
Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancy.
Bone Marrow Transplantation.
42:497-498.
2008
|
|
| 2008
|
Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: Statistical analysis of all published cases and literature review.
Acta Oncologica.
47:962-970.
2008
|
|
| 2008
|
Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation.
Bone Marrow Transplantation.
41:715-720.
2008
|
|
| 2007
|
Renal cell carcinoma: New developments in molecular biology and potential for targeted therapies
2007
|
|
| 2007
|
Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer Cells.
Urology.
69:596-602.
2007
|
|
| 2007
|
Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
Cancer Treatment Reviews.
33:78-84.
2007
|
|
| 2006
|
Woman with a papillary pulmonary lesion and a complex renal cyst
2006
|
|
| 2005
|
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
British Journal of Cancer.
92:2266-2277.
2005
|
|
| 2005
|
Use of complementary and alternative medicine by Brazilian oncologists.
European Journal of Cancer Care.
14:143-148.
2005
|
|
| 2005
|
Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients..
Breast Cancer Research.
7.
2005
|
|
| 2004
|
Simultaneous occurrence of Hodgkin disease and tuberculosis: Report of three cases.
Southern Medical Journal.
97:696-698.
2004
|
|
| 2004
|
Commentary: The quality of randomised controlled trials may be better than assumed
2004
|
|
| 2004
|
Evaluation of non-oncologist physician's knowledge and attitude towards cancer screening and preventive actions.
Revista da Associação Médica Brasileira.
50:257-262.
2004
|
|
| 2004
|
Negative results in cancer clinical trials - Equivalence or poor accrual?.
Contemporary Clinical Trials.
25:525-533.
2004
|
|
| 2003
|
White coat effect in breast cancer patients undergoing chemotherapy.
European Journal of Cancer Care.
12:372-373.
2003
|
|
| 1999
|
Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients.
Acta Haematologica.
102:56-58.
1999
|
|
| 1995
|
Main variations of the extrahepatic biliary system and their application to the so-called "split-liver" transplantation technique.
Revista do Hospital das Clínicas.
50:311-313.
1995
|
|
